Abstract：【Objective】To explore the clinical efficacy and safety of Perampanone in the treatment of refractory epilepsy in adults. 【Methods】A retrospective analysis was conducted on the clinical data of 90 patients with refractory epilepsy admitted to our hospital from January 2018 to March 2024. The patients were divided into the observation group (combined with Perampanone on the basis of conventional antiepileptic drugs, n=49) and the control group (combined with gabapentin on the basis of conventional antiepileptic drugs, n=41) according to different treatment methods. The clinical efficacy, cognitive function, neurological function and changes of cranial nerve-related factors before and after treatment of the two groups were compared, and the occurrence of adverse drug reactions during the treatment period of the two groups was statistically analyzed. 【Results】 The total effective rate of the observation group was 69.39% (34/49), which was higher than that of the control group (48.78%, 20/41), and the difference was statistically significant (P<0.05). After treatment, the MMSE scores of both groups were higher than those before treatment, and the score of the observation group was higher than that of the control group. The difference was statistically significant (P<0.05). The differences in latency and amplitude before and after treatment in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). The differences in serum BDNF, NSE and S100β before and after treatment in the observation group were all higher than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Perampanone has a good clinical efficacy in the treatment of refractory epilepsy in adults. It can improve the cognitive function and neurological function of patients, regulate the levels of cranial nerve-related factors, and has good safety.
张延彬, 宋帅召, 郑文权. 吡仑帕奈片治疗成人难治性癫痫患者的疗效及安全性分析[J]. 医学临床研究, 2025, 42(4): 673-675.
ZHANG Yanbin, SONG Shuaizhao, ZHENG Wenquan. Analysis of the Efficacy and Safety of Perampanone Tablets in the Treatment of Refractory Epilepsy in Adults. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 673-675.
[1] 仲婷,陆明佳,米尔古丽?艾麦特,等. 成人癫痫患者血清miR-146a、miR-125a、TLR4水平及临床意义[J].检验医学与临床,2024,21(16):2362-2366. [2] 陈妍,梁玉婵,黄振华,等. 左乙拉西坦联合丙戊酸钠对成人癫痫患者脑电图、骨代谢和骨密度指标的影响[J].海南医学,2022,33(2):162-165. [3] 裴紫娟,王博文,笱玉兰. 吡仑帕奈单药治疗成人局灶性癫痫的临床疗效及安全性评价[J].实用药物与临床,2023,26(2):132-135. [4] 王丹,李平,陈云,等. 定痫丸联合吡仑帕奈治疗成人局灶性癫痫临床研究[J].中西医结合研究,2023,15(1):13-17. [5] 丛璐璐,赵宗茂.2017年国际抗癫痫联盟癫痫发作和癫痫新分类的简要解读[J].河北医科大学学报,2018,39(9):993-995. [6] FISHER R S, CROSS J H, FRENCH J A, et al. Operational classification of seizure types by the international league against epilepsy: Position paper of the ILAE commission for classification and terminology[J].Epilepsia,2017, 58(4):522-530. [7] 覃百灵,李通,胡敏婷,等. 不同频率重复经颅磁刺激对卒中后癫痫患者的疗效及其对神经功能、认知功能、生活质量的影响[J].神经损伤与功能重建,2023,18(5):304-306. [8] 张忠胜,孔学健. 吡仑帕奈与奥卡西平单药治疗成人局灶性癫痫的有效性和安全性研究[J].癫痫杂志,2024,10(1):39-43. [9] 雒晨宇,孙美珍. 吡仑帕奈单药治疗对癫痫患者睡眠及认知的影响[J].实用药物与临床,2023,26(11):990-994. [10] MEHNDIRATTA M M, GULHANE M, JABEEN S A, et al. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: post hoc analysis of phase Ⅱ and phase Ⅲ double-blind and open-label extension studies in India[J].Epilepsia Open,2021, 6(1):90-101. [11] 白杨,杨越,齐会珍.癫痫患者脑电图异常和血清BDNF、GFAP、miR-7-5p表达特征及与认知功能的关系[J].河北医学,2024,30(4):623-629. [12] SADEGHI M A, HEMMATI S, MOHAMMADI S, et al. Chronically altered NMDAR signaling in epilepsy mediates comorbid depression[J].Acta Neuropathol Commun,2021, 9(1):53-58. [13] 陈思蕊,李军强,党小利,等.吡仑帕奈在癫痫共病治疗中的研究进展[J].中国临床药理学与治疗学, 2024, 29(3):354-359.
2025, Vol. 42 
